Dr Swati Srivastav - Effective Medications for Patients With Chronic Kidney Disease
Dr Swati Srivastav, MD, Fellow in Diabetes, Trained in Endocrine Tech, and professor at SMS Medical College, Jaipur. She shares her view on medications that can be effectively used in patients with renal impairment. SGLT2 inhibitor is a good option for patients with GRF as low as 45 ml/min. There are also some DPP-4 inhibitors, such as linagliptin, that can also be used in such patients.
Dr Sujoy Ghosh - Gliptins Are Effective in Improving Glycaemic Control in Diabetic Patients
Dr Sujoy Ghosh (MBBS, DM-Endocrinology, FRCP, FACE, FICP) – Associate Prof. at Dept. of Endocrinology, Kolkata. He shares his view on the need to achieve good glycemic control in patients with Diabetes Mellitus. Gliptins can be a good option to improve glycaemic control. Verify trial shows that vildagliptin in combination with metformin is effective in diabetes treatment.
Dr Shalini Jaggi - Why Screening of all Pregnant Women for Gestational Diabetes is Important?
Dr Shalini Jaggi, MBBS, Post Graduate Diploma in Endocrinology, FRCP. She is a Diabetologist and General Physician in Delhi and EC member of RSSDI. She gives a brief overview about gestational diabetes and why it is important to control GDM. She emphasizes on screening of all pregnant women for gestational diabetes right at the first point of contact and then after every trimester.
Dr Rakesh Parikh - Early Diagnosis of Metabolic Syndrome to Prevent Ischemic Heart Disease & Stroke
Dr Rakesh R. Parikh, MBBS, General Physician - Acute Upper Respiratory Infection, Viral Infection, and Knee Sprain. He highlights the need to identify people at high risk of Ischemic Heart Disease and Stroke at an early stage. Metabolic syndrome diagnosis by checking waist circumference, fasting plasma glucose, triglycerides, BP, and HDL can be an effective way to identify the risk.
Dr Minal Mohit - Managing Diabetes Using New Molecules Like GLP1 RAs
Dr Minal Mohit MBBS, MD - General Medicine, FRCP - Endocrinology. She is a General Physician, diabetes, thyroid and endocrine disorder specialist in Jaipur with over 10 yrs of experience. She shares her view on managing diabetes by targeting obesity using molecules like GLP1 RAs. The first in the line is Exenatide followed by Liraglutide, Dulaglutide and Semaglutide.
Dr Lily Rodrigues - Screening Tests to Reduce Patients' CV Risk
Dr Lily Rodrigues, MBBS, DNB - General Medicine, experienced General Physician in Kukatpally, Hyderabad. She has over 35 years of experience as a General Physician. She highlights the need of lipid screening, anthropometric measurements, biochemical marker examination in patients every 1-2 yrs. to reduce the risk of Cardiovascular diseases.
Dr Jitendra Patel - Benefits of Oral GLP-1 Analogue Semaglutide
Dr Jitendra Patel, MBBS, MD - Medicine, Consultant Physician, diabetologist and cardiologist at Pruthvi hospital for last 23 yrs. He discusses the benefits of new molecules in the field of diabetes, oral GLP-1 analogue semaglutide, in HbA1c reduction, bodyweight loss, pleiotropic effects, lipid management, and hypertension.
Dr Aravinda Jagdeesha - Early Detection of Prediabetes to Prevent Type 2 diabetes
Dr Aravinda Jagadeesha, MD,MRCP (London), Triple FRCP (London, Glasgow), Immediate past President RSSDI Karnataka chapter, and Consultant Diabetologist. He shared his views on diabetes prevention by three things - test, track and treat. He advices regular blood glucose test for people above 25 yrs. to identify prediabetes in advance.
Prof Dame Anna Dominiczak - Does Polypill Offer Better Blood Pressure Control?
Dame Anna Dominiczak is Regius Professor of Medicine, Honorary Consultant Physician and Non-Executive Member of NHS Greater Glasgow and Clyde Health Board. She discusses the new ISH guidelines that do not really recommend polypills use in reducing blood pressure. The guidelines recommend combination drugs starting from two antihypertensive drugs and adding statin.
Challenges in the Treatment of Hypertension in Patients With Chronic Kidney Disease
Luis M Ruilope is a professor at Autonomous Uni. of Madrid Dept. of Preventative Medicine Public Health and Microbiology, Spain. Using renin-angiotensin system blockers or mineralocorticoid receptor antagonists in patients with chronic kidney disease may increase potassium levels in the body. He highlights the use of potassium binders to lower potassium levels in CKD patients.
Pathogenesis of Type 2 Diabetes
Viktor Jörgens is a medical doctor and Former Executive Director of the European Association for the Study of Diabetes. He discusses the pathogenesis of different forms of type 2 diabetes, which will help to find individualized diabetes treatment. Scientists looked at data at the time of diagnosis of diabetes and were able to find different clusters with different incidences of complications.
Are ACE Inhibitors Safe in Younger Hypertensive Patients?
Professor Alta Schutte is a leading researcher in hypertension and cardiovascular health. She suggests that Angiotensin-converting enzyme (ACE) inhibitors are very effective in younger hypertensive patients. But this medicine is contraindicated in women planning to become pregnant or may become pregnant as it may cause problems in the unborn child.
What Are the First Line Treatment Options for Hypertension?
Prof. Alta Schutte's research interests focus on identifying early markers for the development of hypertension and prevention of hypertension and cardiovascular disease. She recommends ACE inhibitors, ARBs, and calcium channel blockers as first-line treatment of hypertension. However, beta-blockers can be used in countries or areas with limited resources.
Prof. Javed Butler (ESC 2021): EMPEROR Preserved and GUIDE-HF Trials
Prof Javed Butler, chair of the Dept. of Medicine at the Univ. of Mississippi Medical Center, provides some early insights into two clinical trial outcomes in the heart failure world presented at ESC 2021. GUIDE-HF trial looks for CardioMEMS HF System effectiveness in HF patients. EMPEROR Preserved trial looks for Empagliflozin effectiveness in Patients with HFpEF.
Non-Insulin-Producing Human Pancreatic Cells Can Produce Insulin
Pedro L Herrera is a prof. at the Univ. of Geneva Medical School and the director of the university’s Transgenic Core Facility.He provides insight into the plasticity of human pancreatic cells. His recent study has shown that non-insulin-producing human pancreatic cells can be reprogrammed to produce insulin after the loss of beta-cells.
Caution Before Universally Recommending SGLT2i or GLP-1RAs in Inpatient Cardiac Care Setting
SGLT2i and GLP-1RA have clear outcomes benefits in high CV risk patients with diabetes, but the drugs are currently underutilized. However, the side effect profile of these medications must be carefully considered before initiation of these drugs in the hospital. Initiation of drug at the conclusion of hospital stay or at discharge may be safest and most effective approach at this time.
Risk of Acute Kidney Injury in Real-World Use of Dapagliflozin
A study compared the occurrence of acute kidney injury in new users of Dapagliflozin & of comparator GLDs. Comparators incorporated GLDs besides SGLT2 inhibitors or monotherapy of insulin, metformin, or sulfonylureas. Study exhibited that a reduced risk of AKI was correlated with Dapagliflozin than other GLDs and adjusted with findings from Dapagliflozin clinical trials.
SGLT2is and GLP-1RAs—What Are the Benefits?
SGLT2 inhibitors & GLP1RAs should be considered in T2D patients with ASCVD or at high risk regardless of A1c. Empagliflozin, Semaglutide, Liraglutide, Canagliflozin reduced the rate of CV death, non-fatal MI or stroke . Dapagliflozin, Lixisenatide, was not associated with a significant difference in CV events. Substantial evidence exists supporting their safety & efficacy.
Rivaroxaban Plus Aspirin: Mortality in Chronic CAD or PAD
Patients with stable CAD or PAD plus baseline high-risk features experienced greater mortality benefit with rivaroxaban plus aspirin therapy.The authors concluded that combination of rivaroxaban plus aspirin compared to aspirin alone reduced overall and cardiovascular mortality for patients with chronic CAD or PAD. They also concluded that mortality benefits are greater for patients .
Apixaban for Treatment of Embolic Stroke of Undetermined Source (ATTICUS) Randomized Trial
Despite the significant frequency of covert atrial fibrillation, secondary prophylaxis with aspirin is the current standard therapy for ESUS (AF). The efficacy of apixaban in 353 ESUS patients (68.5 yrs old, 51% male) was evaluated. 130 and 120 subjects from apixaban & ASA arms, respectively, complete study. By far, apixaban has been found to be better.
